#1 Clinical Trials Search in Europe

Botensilimab

Botensilimab is an innovative immunotherapy drug currently being studied in clinical trials for the treatment of various advanced cancers. This article explores the ongoing research into botensilimab’s potential as both a monotherapy and in combination with other immunotherapy agents, particularly for solid tumors that have not responded to previous treatments.

Table of Contents

What is Botensilimab?

Botensilimab, also known as AGEN1181, is a new type of immunotherapy drug being studied for the treatment of various types of cancer[1]. It is a specially engineered antibody, which is a type of protein that can target specific molecules in the body. Botensilimab is designed to enhance the body’s immune response against cancer cells[2].

How Does Botensilimab Work?

Botensilimab works by targeting a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) on immune cells. CTLA-4 normally acts as a “brake” on the immune system, preventing it from becoming overactive. By blocking CTLA-4, botensilimab helps to “release the brakes” on the immune system, allowing it to recognize and attack cancer cells more effectively[3].

What makes botensilimab unique is that it has been engineered with a special part called an Fc region. This Fc engineering is designed to make the drug more effective and potentially safer than similar drugs[1].

What Conditions Does Botensilimab Treat?

Botensilimab is being studied for the treatment of various types of advanced cancers, including:

  • Melanoma: A type of skin cancer[2]
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer[3]
  • Colorectal cancer: Cancer of the colon or rectum[4]
  • Pancreatic cancer: Cancer of the pancreas[5]
  • Renal cell carcinoma: A type of kidney cancer[6]
  • Other advanced solid tumors: Various types of cancers that form solid masses[1]

How is Botensilimab Administered?

Botensilimab is given as an intravenous (IV) infusion, which means it is delivered directly into the bloodstream through a vein. The dosage and frequency of administration can vary depending on the specific clinical trial and the condition being treated. In some studies, it is given every 3 weeks, while in others it may be given every 6 weeks[1][3].

Botensilimab in Combination Therapies

Many clinical trials are studying botensilimab in combination with other cancer treatments, particularly with another immunotherapy drug called balstilimab (also known as AGEN2034). Balstilimab targets a different immune checkpoint protein called PD-1[3][2].

The combination of botensilimab and balstilimab is being tested to see if it can provide better results than either drug alone. This approach aims to stimulate the immune system in multiple ways to fight cancer more effectively[6].

Ongoing Clinical Trials

Botensilimab is currently being studied in several clinical trials for different types of cancer. These trials are designed to evaluate:

  • The safety and effectiveness of botensilimab alone and in combination with other treatments[1]
  • The best dosage and schedule for administering the drug[3]
  • How well botensilimab works compared to existing treatments[6]
  • The effects of botensilimab on the immune system and tumor environment[7]

Potential Side Effects

As with all cancer treatments, botensilimab may cause side effects. Because it stimulates the immune system, many of the potential side effects are related to an overactive immune response. Common side effects being monitored in clinical trials include:

  • Fatigue
  • Nausea
  • Diarrhea
  • Skin rashes
  • Inflammation in various parts of the body

It’s important to note that the full range of potential side effects is still being studied in clinical trials. Patients participating in these trials are closely monitored for any adverse reactions[1][2].

Aspect Details
Drug Name Botensilimab (also known as AGEN1181)
Drug Type Fc-engineered anti-CTLA-4 monoclonal antibody
Combination Therapy Often studied with balstilimab (anti-PD-1 antibody)
Cancer Types Studied Non-small cell lung cancer, melanoma, colorectal cancer, endometrial cancer, ovarian cancer, prostate cancer, and other advanced solid tumors
Administration Intravenous infusion
Dosing Schedules Various, including every 3 weeks and every 6 weeks
Primary Objectives Safety, tolerability, optimal dosage, efficacy, effects on tumor microenvironment
Key Outcome Measures Objective Response Rate, Progression-Free Survival, Overall Survival, Duration of Response
Trial Phases Phase 1 and Phase 2 studies
Special Populations Some trials focus on patients with refractory cancers or specific biomarkers

FAQ

  • What is botensilimab? Botensilimab is an Fc-engineered anti-CTLA-4 monoclonal antibody designed to enhance the body's immune response against cancer cells. It is being investigated as a potential treatment for various advanced solid tumors.
  • What types of cancer is botensilimab being tested for? Clinical trials are exploring botensilimab's effectiveness in several cancer types, including non-small cell lung cancer, melanoma, colorectal cancer, endometrial cancer, ovarian cancer, prostate cancer, and other advanced solid tumors.
  • How is botensilimab administered? Botensilimab is typically administered intravenously (IV) in various dosing schedules, such as every 3 weeks or every 6 weeks, depending on the specific trial protocol.
  • Is botensilimab used alone or in combination with other drugs? Botensilimab is being studied both as a monotherapy and in combination with other immunotherapy drugs, particularly balstilimab (an anti-PD-1 antibody). Some trials are also exploring triple combinations with additional agents.
  • What are the main goals of the clinical trials involving botensilimab? The primary objectives of these trials include assessing the safety and tolerability of botensilimab, determining the optimal dosage, evaluating its efficacy in treating various cancers, and studying its effects on the tumor microenvironment and immune response.

Ongoing Clinical Trials on Botensilimab

  • Study Comparing Survival in Patients with Advanced or Metastatic Gastric Cancer Treated with Botensilimab and Balstilimab vs. Standard Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Botensilimab and Balstilimab for Patients with Various dMMR and pMMR Tumors

    Recruiting

    1 1
    Investigated drugs:
    The Netherlands

  • Study of Pre-Operative Treatments with Sotorasib and Drug Combination for Patients with Resectable Colorectal Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

    Not recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on Botensilimab Alone and with Balstilimab or Drug Combination for Patients with Refractory Metastatic Colorectal Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy Spain

Glossary

  • Botensilimab: An Fc-engineered anti-CTLA-4 monoclonal antibody designed to enhance the immune system's ability to fight cancer cells.
  • Balstilimab: A fully human monoclonal antibody that targets programmed cell death protein 1 (PD-1), often used in combination with botensilimab in clinical trials.
  • CTLA-4: Cytotoxic T-lymphocyte-associated protein 4, a protein that helps regulate the immune system and is targeted by botensilimab.
  • PD-1: Programmed cell death protein 1, a protein on the surface of immune cells that is targeted by balstilimab to enhance the immune response against cancer.
  • Immunotherapy: A type of cancer treatment that stimulates the body's immune system to fight cancer cells.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to specific targets in the body, such as cancer cells.
  • Solid tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas, found in various parts of the body.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Neoadjuvant therapy: Treatment given before the main treatment, often to shrink a tumor before surgery.

References

  1. https://clinicaltrials.gov/study/NCT03860272
  2. https://clinicaltrials.gov/study/NCT05529316
  3. https://clinicaltrials.gov/study/NCT06322108
  4. https://clinicaltrials.gov/study/NCT05571293
  5. https://clinicaltrials.gov/study/NCT05630183
  6. https://clinicaltrials.gov/study/NCT05928806
  7. https://clinicaltrials.gov/study/NCT06300463